PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating
metastatic non-small cell lung cancer. Blood samples will also be collected for research
purposes.